Partners and Subsidiaries
In order to strengthen our service capabilities further, we have established collaborations with validated partners for technologies adding additional value to our established services as well as for analyses exceeding the capacity of Redoxis internal resources.
Cellevate is an innovative biotech company that develops the next generation of cell culture systems. The company creates highly porous and consistent networks of nanofibers through a patented manufacturing process. Cells in these networks are allowed to proliferate and interact with other cells in three dimensions (3D), in contrast to the monolayer cultures seen on conventional two dimensional (2D) surfaces.
Cellevates goal is to provide life science researchers with more realistic in-vitro models, for more relevant data and successful research.
Red Glead Discovery
Red Glead Discovery delivers high quality solutions with respect to preclinical services to support small molecule and peptide drug projects. In-house capabilities span across a large part of the drug discovery process chain from screening compounds for Hit identification to optimization of lead compounds towards candidate drugs, such as organic synthesis, medicinal chemistry, peptide chemistry, analytical chemistry, in vitro ADME, assay development & screening, bioanalysis, NMR. Our project management skills and cross-disciplinary capabilities make us a preferred partner for clients that want to develop compounds with high potential to become successful drugs.
Thomas Bäckström has extensive experience working with emulsions and animal models. He saw the need for a quality-controlled emulsion that could be produced independently of the researcher.
Therefore, he started his own company, BTB Emulsions, and developed a device and method that enabled the production of quality emulsions. The Perfect Oil in Water Emulsion Receptacle (POWER) device together with a homogenizer can replace the 2-syringe method to generate perfect emulsions. Redoxis has been part of the evaluation process of this device and have now switched from traditional syringe-connector-syringe preparations to use the POWER system for most of our emulsion preparations with very good results.
ProNoxis AB was founded in 2009 by LU Bioscience AB (LUBio), Karolinska Development AB, and Redoxis AB, as a Redoxis spin-off focusing on developing anti-inflammatory therapeutics targeting activation of the NADPH oxidase complex (NOX2). Since 2012 it is fully owned by Redoxis AB.
ProNoxis focuses on the development of small-molecule drugs to treat chronic inflammation.